High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Sehr, Peter ^a   Rubio, Ivonne ^b   Seitz, Hanna ^b   Putzker, Kerstin ^a   Ribeiro Müller, Lis ^b   Pawlita, Michael ^b   Müller, Martin ^b  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; LUCIFERASE; NEUTRALIZING ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOVINE PAPILLOMAVIRUS TYPE 1; CANCER GRADING; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; REPRODUCIBILITY; SENSITIVITY ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; VIRION; VIRUS NEUTRALIZATION;

ANTIBODIES, VIRAL; CELL LINE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; REPRODUCIBILITY OF RESULTS;

EID: 84885030330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075677     Document Type: Article

References (42)

1. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 100B: 255-313.
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The lancet oncology 11: 1048-1056.
3. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
5. Schiller JT, Lowy DR, (2010) Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 64: 23-41.
6. Gissmann L, (2009) HPV vaccines: preclinical development. Arch Med Res 40: 466-470.
7. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, et al. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369: 1693-1702.
8. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
9. Christensen ND, Kreider JW, (1990) Antibody-mediated neutralization in vivo of infectious papillomaviruses. Journal of virology 64: 3151-3156.
10. Roden RB, Weissinger EM, Henderson DW, Booy F, Kirnbauer R, et al. (1994) Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. Journal of virology 68: 7570-7574.
11. Yeager MD, Aste-Amezaga M, Brown DR, Martin MM, Shah MJ, et al. (2000) Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 278: 570-577.
12. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, (1998) In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. Journal of virology 72: 10298-10300.
13. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2004) Efficient intracellular assembly of papillomaviral vectors. Journal of virology 78: 751-757.
14. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, et al. (1995) Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. Journal of virology 69: 5147-5151.
15. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, et al. (2003) Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clinical and diagnostic laboratory immunology 10: 108-115.
16. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
17. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, et al. (2007) Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). International journal of cancer Journal international du cancer 121: 2794-2800.
18. Buck CB, Thompson CD (2007) Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol Chapter 26: Unit 26 21.
19. Wang QY, Xu YF, Fan DS, Peng QL, Zhang T, et al. (2007) [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine]. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae 29: 584-591.
20. Schmitt M, Pawlita M, (2009) High-throughput detection and multiplex identification of cell contaminations. Nucleic acids research 37: e119.
21. Castro F, Dirks WG, Fahnrich S, Hotz-Wagenblatt A, Pawlita M, et al. (2013) High-throughput SNP-based authentication of human cell lines. International journal of cancer Journal international du cancer 132: 308-314.
22. Waterboer T, Sehr P, Pawlita M, (2006) Suppression of non-specific binding in serological Luminex assays. Journal of immunological methods 309: 200-204.
23. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, et al. (2005) Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clinical chemistry 51: 1845-1853.
24. Sehr P, Müller M, Hopfl R, Widschwendter A, Pawlita M, (2002) HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. Journal of virological methods 106: 61-70.
25. Sehr P, Zumbach K, Pawlita M, (2001) A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. Journal of immunological methods 253: 153-162.
26. Ferguson M, Wilkinson DE, Heath A, Matejtschuk P, (2011) The first international standard for antibodies to HPV 16. Vaccine 29: 6520-6526.
27. Dianna E. Wilkinson ABH, Helena Faust, Gitika Panicke4, Elizabeth R. Unger, Joakim Dillner, Jarunya Ngamkham and the Collaborative Study Group (2012) Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Antibodies to Human Papillomavirus Type 18.
28. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, et al. (2012) Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet infectious diseases 12: 781-789.
29. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, et al. (2012) Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate. PLoS One 7: e39741.
30. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, et al. (2005) Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clinical and diagnostic laboratory immunology 12: 959-969.
31. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, et al. (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937-5949.
32. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, et al. (2011) A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. The Journal of infectious diseases 204: 94-102.
33. Rodriguez AC, Burk R, Herrero R, Hildesheim A, Bratti C, et al. (2007) The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sexually transmitted diseases 34: 494-502.
34. Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, et al. (2004) Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. British journal of cancer 91: 1269-1274.
35. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, et al. (2003) Seroprevalence of human papillomavirus-16,-18,-31, and-45 in a population-based cohort of 10000 women in Costa Rica. British journal of cancer 89: 1248-1254.
36. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, et al. (2009) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human vaccines 5: 705-719.
37. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D, (2011) A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. Journal of virology 85: 13253-13259.
38. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proceedings of the National Academy of Sciences of the United States of America 92: 11553-11557.
39. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, et al. (2008) Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Human vaccines 4: 425-434.
40. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, et al. (2011) The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 409: 348-359.
41. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, et al. (2012) A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clinical and vaccine immunology: CVI 19: 1075-1082.
42. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nature medicine 13: 857-861.